从药物基因组学的兴起谈精准医学的发展
雷小英 - 医学争鸣, 2016 - cqvip.com
在基因组学研究的时代背景下发展起来的药物基因组学, 明确了个体遗传差异对药物作用的影响
, 并提出根据个体遗传差异指导临床用药的革命性医疗新理念, 为精准医学的提出和发展奠定了 …
, 并提出根据个体遗传差异指导临床用药的革命性医疗新理念, 为精准医学的提出和发展奠定了 …
[HTML][HTML] EGFR mutation status and TKI therapy in patients with advanced vulvar cancer: Clinical observations
K Liu - Open Access Library Journal, 2017 - scirp.org
Vulvar cancer is a rare female genital neoplasm representing 5% of all gynecological
malignancies, and occurring most frequently in women between the ages of 65 and 75. The …
malignancies, and occurring most frequently in women between the ages of 65 and 75. The …
[PDF][PDF] Gefitinib anti-cancer drug: A review
SK Savale - Asian J. Biomater. Res, 2017 - researchgate.net
Objective: Gefitinib (GFT) is an orally active selective inhibitor of epidermal growth factor
receptor tyrosine kinase, an enzyme that regulates intracellular signalling pathways …
receptor tyrosine kinase, an enzyme that regulates intracellular signalling pathways …
Functional characterisation of EGFR mutations in cancer
P Harrison - 2021 - repository.icr.ac.uk
Large-scale pan-cancer sequencing of tumour samples has identified a plethora of
epidermal growth factor (EGFR) mutations along the full length of the gene. However …
epidermal growth factor (EGFR) mutations along the full length of the gene. However …
Prognostic Value of PD-L1 in Metastatic NSCLC with EGFR-Sensitizing Mutations: A Benchmark Filipino Cohort Study
HGC Luna, MS Imasa, N Juat, KV Hernandez, TM Sayo… - papers.ssrn.com
Background: The prognostic value of PD-L1 in predicting the treatment outcomes of EGFR-
mutant NSCLC has been reported, but clinical results remain primarily inconsistent. Whether …
mutant NSCLC has been reported, but clinical results remain primarily inconsistent. Whether …
[PDF][PDF] Progress in target therapy of advanced non-small cell lung cancer
L Zhang, R Cao - tmrjournals.cn
Lung cancer is one of the most common malignant tumors, and its morbidity and mortality
are relatively high. Especially for small cell lung cancer (SCLC), the mortality rate is between …
are relatively high. Especially for small cell lung cancer (SCLC), the mortality rate is between …
[PDF][PDF] Đánh giá đáp ứng điều trị bước một ung thư phổi không tế bào nhỏ bằng TKIs sau 3 tháng tại Bệnh viện Hữu nghị= Result of firstline treatment of non-small cell …
CH Lê, TKT Lê - 2022 - thuvienlamdong.org.vn
ĐÁNH GIÁ ĐÁP ỨNG ĐIỀU TRỊ BƯỚC MỘT UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ BẰNG
TKIS SAU 3 THÁNG TẠI BỆNH Page 1 HỘI THẢO HÀNG NĂM PHÒNG CHỐNG UNG THƯ …
TKIS SAU 3 THÁNG TẠI BỆNH Page 1 HỘI THẢO HÀNG NĂM PHÒNG CHỐNG UNG THƯ …
Simple column purification technique for the fully automated radiosynthesis of 2-[18F] fluorine-N-(3-bromophenyl)-6,7-dimethoxyquinazoline-4-amine [2-18F …
Z Liu, J Jin, G Wang, M Dong, Q Zhang, K Zhao… - … of Radioanalytical and …, 2016 - Springer
18 F-PD153035 was synthesized by nucleophilic displacement of 4-(3-bromoanilino)-6, 7-
dimethoxyquinazoline-2-trimethylammonium chloride with 18 F−. Biodistribution and micro …
dimethoxyquinazoline-2-trimethylammonium chloride with 18 F−. Biodistribution and micro …
[PDF][PDF] Dlouhodobý efekt erlotinibu u pacienta s nemalobuněčným karcinomem plic ve 3. linii protinádorové léčby-kazuistika
N Šťastná, L Jakubíková, K Brat - 2020 - linkos.cz
Východiska: Maligní tumory trachey, plic a bronchů jsou druhým nejčastějším typem
novotvarů v České republice. Přibližně tři čtvrtiny případů jsou dia gnostikovány v …
novotvarů v České republice. Přibližně tři čtvrtiny případů jsou dia gnostikovány v …
PERBANDINGAN EFIKASI GEFITINIB DAN ERLOTINIB PADA PASIEN KANKER PARU JENIS KARSINOMA BUKAN SEL KECIL DI POLI ONKOLOGI SATU ATAP RS …
AA Laitupa - 2019 - repository.unair.ac.id
Latar Belakang Kanker paru sering terjadi setelah kanker payudara dan kanker prostat.
Gefitinib dan Erlotinib adalah dua EGFR TKI yang memiliki mekanisme yang sama dan …
Gefitinib dan Erlotinib adalah dua EGFR TKI yang memiliki mekanisme yang sama dan …